Article info

Download PDFPDF

Original research
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Authors

  • Anne W J Martens Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Susanne R Janssen Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ingrid A M Derks Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Homer C Adams III Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Liat Izhak Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Roel van Kampen Department of Internal Medicine, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands PubMed articlesGoogle scholar articles
  • Sanne H Tonino Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Eric Eldering Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Gerritje J W van der Windt Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Arnon P Kater Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Arnon P Kater; a.p.kater{at}amsterdamumc.nl
View Full Text

Citation

Martens AWJ, Janssen SR, Derks IAM, et al
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Publication history

  • Accepted April 26, 2020
  • First published June 24, 2020.
Online issue publication 
June 24, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.